Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapyversus chemotherapy with CMF as adjuvants in operable breast cancer
- 1 September 1991
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 19 (1) , 15-21
- https://doi.org/10.1007/bf01975200
Abstract
In this study, patients with operable breast cancer T2 or T3, treated by mastectomy + axillary dissection and with invaded axillary nodes (N+), were randomized to receive either: 1) postoperative locoregional and pelvic radiotherapy (RX) and Poly(A).Poly(U) (AU), 60 mg IV once a week for 6 weeks, or 2) CMF (cyclophosphamide 100 mg/sqm P.O. on days 1–14, methotrexate 40 mg/sqm IV on day 1 and 8, fluorouracil 600 mg/sqm IV on day 1 and 8; monthly cycle, for 6 months. Between March 1982 and December 1985, 517 patients were enrolled, 257 of whom were treated by RX + AU and 260 with CMF. The main clinical, pathological and prognostic characteristics were equally distributed in the two groups. The present analysis was conducted after a mean follow-up of 69 months (S.D.=13). There was no significant difference in overall survival (OS) between the two groups (test adjusted by center and menopausal status); the five-year OS rate was 74% in the RXAU group and 77% in the CMF group. Relapse-free survival (RFS) was significantly higher (p=0.05) in the RXAU group compared to the CMF group; the five-year RFS rates were 57% and 46% in the two groups respectively. This short, well-tolerated combined RXAU treatment appears to be as efficient as CMF and might offer an alternative to chemo- or hormonotherapy, in case of contraindications to these treatments.Keywords
This publication has 17 references indexed in Scilit:
- Adjuvant treatment of operable stomach cancer with polyadenylic·polyuridylic acid in addition to chemotherapeutic agents: A preliminary reportInternational Journal of Immunopharmacology, 1990
- Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trialsInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- Postoperative radiotherapy in breast cancer—long-term results from the Oslo studyInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial.BMJ, 1984
- Multimodal treatment in operable breast cancer: five-year results of the CMF programme.BMJ, 1981
- ADJUVANT TREATMENT WITH POLYADENYLIC-POLYURIDYLIC ACID (POLYA.POLYU) IN OPERABLE BREAST CANCERThe Lancet, 1980
- Estimation of confidence limits for the cumulative probability of survival in life table analysisJournal of Chronic Diseases, 1978
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerNew England Journal of Medicine, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958